ArticleMolecular cancer therapeutics2026

Preclinical Activity of the DLL3-Targeted T-cell Engager MK-6070 in Neuroendocrine Prostate Cancer.

Sheng-Yu Ku et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.